Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Charles River Laboratories International, Inc. logo

NYSE · CRL

Charles River Laboratories International, Inc.

Healthcare · Medical - Diagnostics & Research

$376.10

Down-$16.69 (-4.44%)

Updated Oct 31, 2026, 1:28 AM

SID Score

6.8/10

Composite research score

Smart Money

54/100

Neutral

Market cap
9.57B
P/E ratio
-137.99
Dividend yield
0.00%
52-week range
$146.20 – $379.63
Volume
887.34K
Avg. volume
1.03M

Price performance · CRL

CRL price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

CRL closed at $376.10 after 20 trading sessions, up 29.60% for the selected period.

Last close
$376.10
Period change
+29.60%
Period low
$290.19
Period high
$376.10
Daily close
View OHLC price history
CRL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$375.00$379.63$368.63$376.10887.34K
Oct 28, 2026$360.01$378.23$360.01$373.981.3M
Oct 27, 2026$351.95$359.89$351.95$358.841.16M
Oct 26, 2026$347.59$357.77$345.89$357.271.18M
Oct 23, 2026$337.78$347.195$332.17$345.37822.3K
Oct 22, 2026$341.43$351.21$337.78$339.662.66M
Oct 21, 2026$313.83$348.95$313.83$344.872.75M
Oct 20, 2026$308.84$317.59$304.00$315.451.27M
Oct 19, 2026$303.33$305.99$297.56$300.02506.63K
Oct 16, 2026$306.09$308.83$296.3537$300.15674.59K
Oct 15, 2026$301.81$309.475$295.40$306.24928.44K
Oct 14, 2026$297.53$310.53$296.00$302.00941.77K
Oct 13, 2026$301.00$302.77$295.15$299.02753.33K
Oct 12, 2026$301.80$303.10$299.2718$301.86543.77K
Oct 9, 2026$294.60$305.205$294.60$301.79679.86K
Oct 8, 2026$297.01$298.27$288.425$298.001.18M
Oct 7, 2026$303.38$305.18$294.28$300.301.24M
Oct 6, 2026$319.80$333.295$300.01$304.961.92M
Oct 5, 2026$292.05$312.26$292.02$310.771.31M
Oct 2, 2026$287.91$290.6125$285.75$290.19445.52K

Latest CRL news

The latest Smart Investors Daily articles mentioning CRL.

Stock researchCompany · Overview

CRL research

Overview

Company profile and research snapshot.

Company profile

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$191.50
Implied upside
—
Analysts
22
CRL recent ratings
DateFirmRatingTarget
Oct 13, 2026Morgan StanleyOverweight—
Sep 30, 2026UBSBuy—
Sep 28, 2026JefferiesBuy—
Sep 25, 2026Deutsche BankBuy—
Sep 25, 2026Evercore ISI GroupOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Global Clinical Trials Market Size, Share, Growth Trends, and Forecast, 2026-2035 | Clinical Trials Market set to more than Double to $144.4bn as Drugmakers Lean on Outside Researchers

New Report puts the market at $66.3bn in 2025, with oncology accounting for 38.3% and North America just over half, though patchy insurer coverage and infrastructural barriers remain stubborn obstacles for IQVIA, ICON, Medpace and Charles River LaboratoriesDublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Clinical Trials Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Clinical trials remain integral to drug develo

Yahoo · Oct 22, 2026

Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the U.S. Food and Drug Administration (FDA) and Charles River Laboratories to advance the science used to evaluate a medicine's abuse potential, or the likelihood that it could be abused. The research aims to support safer drug development and more informed regulatory decisions.

Yahoo · Oct 22, 2026

3 mid-cap stocks walking a fine line

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By